Cookson Peirce & Co. Inc. Grows Position in Boston Scientific Co. (NYSE:BSX)

Cookson Peirce & Co. Inc. lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 0.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 259,018 shares of the medical equipment provider’s stock after buying an additional 1,813 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Boston Scientific were worth $23,135,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its stake in Boston Scientific by 5.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 11,323 shares of the medical equipment provider’s stock worth $949,000 after purchasing an additional 580 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Boston Scientific by 18.1% in the third quarter. Van ECK Associates Corp now owns 57,894 shares of the medical equipment provider’s stock valued at $5,063,000 after purchasing an additional 8,882 shares during the last quarter. QRG Capital Management Inc. lifted its position in Boston Scientific by 21.6% during the third quarter. QRG Capital Management Inc. now owns 104,462 shares of the medical equipment provider’s stock worth $8,754,000 after buying an additional 18,573 shares in the last quarter. PDS Planning Inc boosted its stake in Boston Scientific by 2.7% during the third quarter. PDS Planning Inc now owns 7,361 shares of the medical equipment provider’s stock worth $617,000 after buying an additional 192 shares during the last quarter. Finally, World Equity Group Inc. purchased a new stake in Boston Scientific in the 3rd quarter valued at $270,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 137,322 shares of company stock valued at $14,321,068. 0.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BSX shares. Raymond James lifted their price target on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Canaccord Genuity Group lifted their target price on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Wells Fargo & Company increased their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Morgan Stanley increased their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average price target of $108.91.

Boston Scientific Stock Performance

Shares of BSX stock opened at $103.57 on Wednesday. The firm has a 50 day moving average of $99.82 and a two-hundred day moving average of $90.79. The stock has a market capitalization of $152.85 billion, a PE ratio of 82.86, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.